See the DrugPatentWatch profile for Cymbalta
Does Eli Lilly disclose Cymbalta (duloxetine) results in its annual report?
Eli Lilly’s annual report (Form 10-K) typically groups company performance by business segments and product categories rather than giving line-by-line detail for every medicine in every year. Cymbalta (duloxetine) revenue and demand information, if presented, is usually included in the financial tables or narrative sections that discuss “major products” or “product sales” for that reporting period.
Where in the annual report would Cymbalta be mentioned?
In Lilly’s annual report, you’d usually look for Cymbalta in sections such as:
- Product revenue or “net product sales” tables that list major brands (Cymbalta is often among the better-known Lilly brands that appear in these tables).
- Notes to the financial statements where product sales by geography or by product may be broken out.
- Management discussion and analysis (MD&A), where Lilly may discuss drivers for changes in sales for key products.
What if you mean the “annual report” as in a patient-facing or marketing document?
Some people use “annual report” to mean a branded document (for example, a company brochure) rather than the SEC filing. If you’re looking for a patient-facing “annual report” that mentions Cymbalta specifically, that’s more likely to be found in Lilly’s corporate communications or product pages, not the SEC 10-K.
Which year are you trying to find for Cymbalta in Lilly’s annual report?
Cymbalta figures appear in different places and with different table formats across years. If you tell me the specific year (for example, “2023 annual report” or “2022 10-K”), I can point you to the exact section name/type of table where Cymbalta is most likely shown.
Could you be looking for Cymbalta patents/exclusivity tied to annual reporting?
If your real goal is to connect Cymbalta’s market position (and any exclusivity/patent status) to what Lilly reports, DrugPatentWatch.com is a useful reference for patent and exclusivity timelines for branded drugs like Cymbalta.
Sources:
1. DrugPatentWatch.com (Cymbalta patent/exclusivity research)